Anagrelide - CAS 68475-42-3
Catalog number: 68475-42-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Phosphodiesterase (PDE)
Anagrelide is a phosphodiesterase inhibitor with antiplatelet activity with IC50 value of 36 nM for inhibition of phosphodiesterase 3. It inhibits the maturation of megakaryocytes into platelets, reducing both megakaryocyte hyperproliferation and differentiation. It is antithrombocythemic used for the treatment of overproduction of blood platelets. It is a synthetic quinazoline derivative and is used as is a platelet-reducing agent. It reduces platelet production through a decrease in megakaryocyte maturation. It inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. It is a drug used for the treatment of essential thrombocytosis or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. It was developed by Shire and has been listed.
Ivory powder
6,7-Dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one;6-Chloro-1,2,3,5-tetrahydro iMidazo [2,1-b]quinazolin-2-one;Agrelin;Agrylin;Xagrid;Shire;Thromboreductin
Soluble in DMSO, not in water
-20°C Freezer
Anagrelide is used for the treatment of overproduction of blood platelets. It is a drug used for the treatment of essential thrombocytosis or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.
Quality Standard:
In-house standard
Kilograms to Tons
Boiling Point:
376.5°C at 760 mmHg
Melting Point:
280 °C
1.77±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
Current Developer:
Anagrelide was developed by Shire and has been listed.
1.Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S1, Tefferi A1. Blood Cancer J. 2015 Nov 13;5:e366. doi: 10.1038/bcj.2015.95.
Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-ABL1-negative myeloproliferative neoplasms and are characterized by relatively long median survivals (approximately 14 and 20 years, respectively). Potentially fatal disease complications in PV and ET include disease transformation into myelofibrosis (MF) or acute myeloid leukemia (AML). The range of reported frequencies for post-PV MF were 4.9-6% at 10 years and 6-14% at 15 years and for post-ET MF were 0.8-4.9% at 10 years and 4-11% at 15 years. The corresponding figures for post-PV AML were 2.3-14.4% at 10 years and 5.5-18.7% at 15 years and for post-ET AML were 0.7-3% at 10 years and 2.1-5.3% at 15 years. Risk factors cited for post-PV MF include advanced age, leukocytosis, reticulin fibrosis, splenomegaly and JAK2V617F allele burden and for post-ET MF include advanced age, leukocytosis, anemia, reticulin fibrosis, absence of JAK2V617F, use of anagrelide and presence of ASXL1 mutation.
2.Influence of platelet and white blood cell counts on major thrombosis - Analysis from a patient registry in Essential Thrombocythemia.
Buxhofer-Ausch V1,2, Steurer M3, Sormann S4, Schloegl E5, Schimetta W6, Gisslinger B1, Ruckser R7, Gastl G3, Gisslinger H1. Eur J Haematol. 2016 Apr 1. doi: 10.1111/ejh.12759. [Epub ahead of print]
OBJECTIVES: Although guidelines recommend normalization of platelet counts as an appropriate endpoint for treatment in high-risk essential thrombocythemia (ET), retrospective studies could not prove a correlation of diagnostic platelet counts with an increased thrombotic rate. There is, however, an increasing evidence that leukocytosis is an important risk factor for arterial thrombosis in myeloproliferative neoplasms.
3.Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D1, Mascarenhas J. Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216.
PURPOSE OF REVIEW: Management of polycythemia vera and essential thrombocythemia requires understanding of the key concepts regarding diagnosis, risk stratification, and management.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products

(CAS: 298680-25-8)

RPL 554 is a potent and selective PDE3/4 inhibitor for respiratory diseases, particularly in patients with asthma.

CAS 171599-83-0 Sildenafil Citrate

Sildenafil Citrate
(CAS: 171599-83-0)

Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...

CAS 224785-90-4 Vardenafil HCl Trihydrate

Vardenafil HCl Trihydrate
(CAS: 224785-90-4)

Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively. Vardenafil was co-marketed by Bayer Pharmaceu...

CAS 115344-47-3 Siguazodan

(CAS: 115344-47-3)

Siguazodan is a selective phosphodiesterase 3 (PDE3) inhibitor (IC50 = 117 nM). Siguazodan acts as a potent vasodilator.

CAS 111786-07-3 RGW2938

(CAS: 111786-07-3)

A phosphodiesterase inhibitor

CAS 37762-06-4 Zaprinast

(CAS: 37762-06-4)

Zaprinast is a cyclic-GMP phosphodiesterase inhibitor with selectivity for PDE6, 5, 11 and 9 (IC50 = 0.15, 0.76, 12.0 and 29.0 μM, respectively). C-GMP acts as ...

CAS 225100-12-9 PDE IV-IN-1

(CAS: 225100-12-9)

An inhibitor of phosphodiesterase IV with potential for the treatment of asthma, COPD or other inflammatory diseases.

CAS 58337-38-5 EHNA hydrochloride

EHNA hydrochloride
(CAS: 58337-38-5)

EHNA hydrochloride is a selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 μM) and also an inhibitor of adenosine deaminase. EHNA i...

Chemical Structure

CAS 68475-42-3 Anagrelide

Quick Inquiry

Verification code

Featured Items